Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06901518 · ClinicalTrials.gov registry record · Phase 4
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
A Phase 4 study, sponsored by Albany Medical College.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT06901518 is a Phase 4 study that has completed, run by Albany Medical College. The registered enrollment target is 25 participants.
The verdict
NCT06901518, a Phase 4 study, has completed, sponsored by Albany Medical College.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this pilot, open-label clinical trial is to determine whether the addition of galcanezumab-gnlm to stable conventional headache treatment will reduce the number of monthly migraine days in participants who have experienced a traumatic brain injury and since developed post-traumatic, migrainous headaches. The main questions it aims to answer are: * if galcanezumab-gnlm is effective in reducing the frequency and severity of post-traumatic headaches with migraine features in study participants * if galcanezumab-gnlm reduces the impact of migraine on the daily life of the study participants Participants will complete five clinic visits over the study. Study participants will * complete a baseline visit including a HIT-6 Headache Impact Test score * complete a headache diary for 4 weeks to record the frequency and severity of migrainous headaches and other information * if determined to be eligible for the trial, undergo a brief physical exam and receive treatment with galcanezumab-gnlm, with a loading dose of 240mg delivered subcutaneously * receive two subcutaneous treatments with galcanezumab-gnlm (120mg) 4 weeks apart * complete a final study visit with a brief physical exam and HIT-6 Headache Impact Test score
Interventions
- DRUG Galcanezumab-Gnlm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06901518
The ClinicalTrials.gov registry entry for NCT06901518 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany Medical College, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galcanezumab-Gnlm is the first listed.
NCT06901518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06901518 about?
NCT06901518 is a clinical study titled "The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches". The goal of this pilot, open-label clinical trial is to determine whether the addition of galcanezumab-gnlm to stable conventional headache treatment will reduce the number of monthly migraine days in participants who have experienced a traumatic brain injury and since developed post-traumatic, migr...
What is the current status of trial NCT06901518?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2020-08-10. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT06901518?
The interventions under investigation include: Galcanezumab-Gnlm (DRUG).
Who is sponsoring clinical trial NCT06901518?
This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.